The review criterion is proposed in this combined notice, rather than individual program announcements, to provide consistent review of all primary care medical education grant applications. An announcement will be made in the HRSA Preview for grant programs which will conduct competitive cycles in FY 1998.

The comment period is 30 days. All comments received on or before October 3, 1997 will be considered before the final review criteria are established. Written comments should be addressed to: Enrique Fernandez, M.D., Division of Medicine, Bureau of Health Professions, Health Resources and Services Administration, Parklawn Building, Room 1A-20, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 443-1467, FAX: (301) 443-8990.

All comments received will be available for public inspection and copying at the Division of Medicine, at the above address, weekdays (Federal holidays excepted) between the hours of 8:30 a.m. and 5:00 p.m.


Claude Earl Fox,
Acting Administrator.

[FR Doc. 97-23373 Filed 9-2-97; 8:45 am]
BILLING CODE 4160-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Cancer Prevention Control and Surveillanc.
Date: September 11-12, 1997.
Time: 9 a.m. to 3 p.m.
Place: The Bethesda Ramada Hotel, 8400 Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Kevin Ryder, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 611D, 6130 Executive Boulevard, M/S 7410, Bethesda, MD 20892-7410, Telephone: 301/402-2785.

Purpose/Agenda: To evaluate and review a grant application. The meeting will be closed in accordance with the provision set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Proposal and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the application, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Dated: August 26, 1997.

LaVeen Ponds,
Policy Analyst, NIH, National Cancer Institute Special Emphasis Panel Office.

[FR Doc. 97-23284 Filed 9-2-97; 8:45 am]
BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Evaluation of Chemopreventive Agents by In vitro Techniques.
Date: October 5-6, 1997.
Time: October 5-6, 8 a.m. to 6 p.m.
Place: The Bethesda Ramada Hotel, 8400 Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Kevin Ryder, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 611D, 6130 Executive Boulevard, M/S 7410, Bethesda, MD 20892-7410, Telephone: 301/402-2785.

Purpose/Agenda: To evaluate and review a grant application. The meeting will be closed in accordance with the provision set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Proposal and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the application, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Dated: August 26, 1997.

LaVeen Ponds,
Policy Analyst, NIH, National Cancer Institute Special Emphasis Panel Office.

[FR Doc. 97-23287 Filed 9-2-97; 8:45 am]
BILLING CODE 4140-01-M